Article

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection

2016-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b7dd3300-38ea-5cb9-a3e5-5b9597cda482
DOI: 10.1016/s0168-8278(16)01700-1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

High Svr Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 InfectionDOI 10.1016/s0168-8278(16)01700-1Read

100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with CirrhosisSemantic proximity Read

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.Semantic proximity Read

High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I StudySemantic proximity Read

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSISSemantic proximity Read

7 BOCEPREVIR IN ADDITION TO STANDARD OF CARE ENHANCED SVR IN HEPATITIS C VIRUS (HCV) GENOTYPE-1 WITH ADVANCED FIBROSIS/CIRRHOSIS: SUBGROUP ANALYSIS OF SPRINT-2 AND RESPOND-2 STUDIESSemantic proximity Read

New antiviral agents for the treatment of hepatitis C: ABT-450.Semantic proximity Read

High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection.Semantic proximity Read

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read

New Drug Treats All Genotypes of Chronic HCV.Semantic proximity Read

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosisSemantic proximity Read

Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.Semantic proximity Read

Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.Semantic proximity Read